The antitumor activity of low molecular weight tyrosine kinase inhibitors (TKIs) has been studied thoroughly in many EGFR overexpressing solid tumors: non-small cell lung cancer (NSCLC), pancreatic cancer, glioblastoma and head and neck cancer. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.